At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 163 enrolled
Drug / intervention
Dapsone; Tretinoin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris
In Brief
A Phase 4 clinical trial evaluating Dapsone; Tretinoin and Tretinoin for Acne Vulgaris. Completed, enrolled 163 participants across 1 site.
Detailed Summary
A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tretinoin gel 0.025% compared with tretinoin gel 0.025% monotherapy in treating moderate to severe facial acne vulgaris
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedFeb 2009
Primary CompletionAug 2009
TodayJul 2026
First PostedFeb 3, 2009
Enrollment StartDec 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.4 years ago
Interventions
Dapsone; Tretinoindrug
Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
Tretinoindrug
Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks